Richard Anthony Cunningham - 06 Oct 2023 Form 4 Insider Report for Anebulo Pharmaceuticals, Inc. (ANEB)

Role
Chief Executive Officer, Director
Signature
/s/ Daniel George, Attorney-in-Fact
Issuer symbol
ANEB
Transactions as of
06 Oct 2023
Net transactions value
$0
Form type
4
Filing time
11 Oct 2023, 17:25:20 UTC
Previous filing
16 Sep 2022
Next filing
10 Dec 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANEB Stock Option (right to buy) Award $0 +600,000 $0.000000 600,000 06 Oct 2023 Common Stock 600,000 $3.03 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option will vest and become exercisable as follows: ratably in 16 quarterly installments (37,500 per installment) on the first day of each calendar quarter commencing with January 1, 2024, such that option will be full vested on October 1, 2027.